The Pharmaceutical Market : China

1
The Pharmaceutical Market China 

• Bharat Book Bureau

2
Summary

• Lowering drug prices remains a top priority
  for health authorities. The National Development
  and Reform Commission (NDRC) implemented two
  rounds of drug price reductions in 2011, one in
  March and the other in September. Most of the
  drugs reduced were manufactured by
  multinationals, which had previously not been
  subject to pricing controls. In terms of
  regulatory developments, the SFDA started to
  inspect overseas manufacturing facilities in
  November 2011, as the agency seeks to align its
  practices with international standards. In July
  2011, the MoH revealed that it may introduce
  mandatory licensing policy to secure cheaper
  drugs for HIV/AIDS patients, as part of the
  countrys universal health coverage programme.

3
Continue

• The highly fragmented drug distribution industry
  in China continued to see consolidation in 2011.
  This is part of the governments 12th Five-Year
  Plan 2011-2015, to strengthen the national drug
  distribution industry by actively supporting
  acquisitions, mergers and reorganisations. There
  were a number of competitive strategies completed
  in the second half of 2011 GPHG acquired Qingdao
  Likang Pharmaceutical Company and Shandong Hua
  Wei Pfizer signed a drug distribution agreement
  with Jointown Alliance Boots signed a letter of
  intent to acquire a stake in Nanjing
  Pharmaceutical and Shanghai Pharmaceutical Group
  strengthened its drug distribution in Northern
  China through a large capital expenditure.

4
Continue

• Espicom projects that the Chinese
  pharmaceutical market will grow by a moderate
  double-digit figure between 2012 and 2017. China
  will be the largest pharmaceutical market in the
  Asia Pacific region, overtaking Japan in 2016.
  China will represent over a third of the Asia
  Pacific regions total pharmaceutical market in
  2017. A number of Chinese pharmaceutical
  manufacturers have witnessed massive growth in
  recent years and have expanded their operations
  both domestically and abroad. The top 10 local
  pharmaceutical manufacturers, including China
  Pharmaceutical Group, Harbin Pharmaceutical
  Group, North China Pharmaceutical and Shanghai
  Pharmaceuticals, had collective revenue of around
  US10.0 billion in 2010.

5
Continue

• PROVIDING STRATEGIC MARKET ANALYSIS EVERY
  MONTHEspicom's highly-regarded world
  pharmaceutical market research reports provide
  enhanced strategic intelligence in a
  user-friendly format. Each report provides
  in-depth information, setting the pharmaceutical
  market in context. The reports provide
• Market size and trends impacting the development
  of the market.
• Five-year projections for market indicators such
  as health spending.
• Regulations on drug applications approvals,
  pricing reimbursement as well as wholesaling
  and retail.
• Specialised intelligence on generics and
  biological medicines.
• Foreign and local company profiles

6
Table of Contents

• SFDA Starts Overseas Factory Inspections..24
• First China Pharmaceutical Group.36
• Hospitals by Region Municipality, 2008. 18
• China Pharmaceutical Group Operating Results,
  2006-2010 (HK 000s).80
• North China Pharmaceutical Operating Results,
  2006-2010 (CNY 000s).. 83
• China Pharma Revenue by Therapeutic Area,
  2009-2010 (US 000s).94

7
For more information

• Kindly visit on
• http//www.bharatbook.com/market-research-rep
  orts/healthcare-market-research-report/the-pharmac
  eutical-market-china.html
• Or visit
• Bharat Book
  Bureau Phone
  91 22 27810772, 27810773
  Fax [phone]
  E-mail info_at_bharatbook.com
  Website
  www.bharatbook.com
  Twitter https//twitter.com/BharatBook
  Blog
  http//www.bharatbook.com/market-reports-blog/